Head-to-head evidence
VCT220 vs ZT006
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
VCT220
Developed by Ji Xing Pharmaceuticals (CORXEL) under a licence from Vincentage Pharma
NCT06569355 · Phase 2 · completed
This Phase 2 trial randomly assigned 250 people with obesity or overweight to one of several VCT220 doses or placebo, with participants, carers, investigators and outcome assessors unaware of assignment. The primary measure was percentage change in body weight at week 16. Weight fell by between 5.8% and 9.7% across the VCT220 dose groups against 1.6% on placebo, with reductions of 9.7% and 9.4% at the two 160 mg schedules (p of 0.001 or lower).
ZT006
Developed by Beijing QL Biopharmaceutical
NCT07307638 · Phase 1 · completed
This is a randomized, blinded, placebo-controlled trial, but its primary endpoints are adverse-event rates rather than a weight-loss outcome, and no results have been posted yet, so its effect on body weight is unknown.
Next expected readout: December 2026 · NCT07230132 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: VCT220's landscape · ZT006's landscape